The Ramco Cements. Institutional Equities. Event Update BUY

Similar documents
EBITDA 2,503 2,904 (13.8) 2,722 (8.0) EBITDA

Dalmia Bharat Enterprises

ACC. Institutional Equities. Event Update. Capacity Expansion To Consolidate Presence In Central India ACCUMULATE

Indian Oil Corporation

EBITDA 6,223 6,511 (4.4) 5, EBITDA

EBITDA 1,548 1,814 (14.7) 1,561 (0.8) EBITDA

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Institutional Equities

Jamna Auto Industries

Gillette India. Institutional Equities. 1QFY18 Result Update

Dalmia Bharat Enterprises

Colgate-Palmolive (India)

EBITDA 5,076 3, , EBITDA

EBITDA 1,585 1,917 (17.3) 1,673 (5.2) EBITDA

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY

Dalmia Bharat Enterprises

Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY

Indian Oil Corporation

Thermax. Institutional Equities. 3QFY18 Result Update. Healthy Execution, But Margins Disappoint SELL

Punjab National Bank

South Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018

Mold-Tek Packaging. Institutional Equities. Conference Update. Promising Growth Outlook BUY

Mangalam Cement. Institutional Equities. 3QFY18 Result Update. Higher Operating costs Hurt Performance BUY

Bata India. Institutional Equities. 1QFY19 Result Update BUY

Eicher Motors. Institutional Equities. Management Meet Update BUY. Reuters: EICH.NS; Bloomberg: EIM IN

Punjab National Bank

Institutional Equities

Nestle India. Institutional Equities. 1QCY18 Result Update. Resurgence Continues BUY. Sector: FMCG CMP: Rs8,981 Target Price: Rs10,700 Upside: 19%

Institutional Equities

26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN

Voltas. Institutional Equities. 1QFY19 Result Update. EMPS Shines, UCP Proves Its Mettle Again ACCUMULATE

Institutional Equities

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Institutional Equities

Swaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE

TVS Motor Company. Institutional Equities. 3QFY19 Result Update SELL

Timken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy

PNB Housing Finance. Institutional Equities. 4QFY18 Result Update BUY. Continued Display of Embedded Scalability. 4 May 2018

Institutional Equities

Karnataka Bank. Institutional Equities. 4QFY18 Result Update. Plucky Bank And Low Hanging Fruit BUY. 17 May Reuters: KBNK.NS; Bloomberg: KBL IN

Bharat Financial Inclusion

Manappuram Finance. Institutional Equities. 3QFY18 Result Update. The Glitter Is Back In Gold Loans BUY. 9 February 2018

Hindustan Unilever. Institutional Equities. 4QFY18 Result Update

Institutional Equities

Crompton Greaves. Institutional Equities. 4QFY15 Result Update ACCUMULATE. Overseas Losses Continue; More Business Exits Likely

Dabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE

Muthoot Finance. Institutional Equities. 1QFY18 Result Update. Gold Loan Business Continues To Glitter BUY. 10 August 2017

Hindustan Unilever. Institutional Equities. 1QFY19 Result Update

2,09,057 1,85,859 2,17, (4.1) NIM

3,746 2,551 3, NIM

Crisil. Institutional Equities. 3QCY17 Result Update ACCUMULATE. Weak SME Rating Revenues & Currency Movement Play Spoilsport

Muthoot Finance. Institutional Equities. 2QFY18 Result Update BUY

Institutional Equities

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Institutional Equities

Muthoot Finance. Institutional Equities. 3QFY18 Result Update. Funding Cost Decline Combines With Operating Leverage BUY.

18,948 15,784 18, NIM

9,500 7,914 8, NIM

Institutional Equities

Institutional Equities

CARE Ratings. Institutional Equities. 2QFY18 Result Update BUY

IFB Industries. Institutional Equities. 3QFY18 Result Update. Healthy Revenues, Strong Gross Margin; Retain Buy BUY.

Bata India. Institutional Equities. Management Meet Update. On Right Track ACCUMULATE. Sector: Retail CMP: Rs692 Target Price: 696 Upside: 1%

Bajaj Electricals. Institutional Equities. 3QFY15 Result Update

Dabur India. Institutional Equities. 1QFY19 Result Update

Manappuram Finance. Institutional Equities. 3QFY17 Result Update BUY

Initiating Coverage. Uflex Ltd.

Cement Sector 27 February 2018

Institutional Equities

Sequent Scientific. Institutional Equities. 1QFY19 Result Update BUY

Muthoot Finance. Institutional Equities. 2QFY19 Result Update. Weak quarter not structural in any way BUY. 10 December 2018

EBITDA 5,019 4,211 5, EBITDA

Muthoot Finance. Institutional Equities. 1QFY19 Result Update

93,707 77,814 90, NIM

PNB Housing Finance. Institutional Equities. 2QFY19 Result Update BUY. Relatively Soft Quarter Not Structural In Nature.

E&P To Stay Strong; Consumer Segment To Revive

V-Guard Industries. Institutional Equities. Conference-call Update BUY. Sector: White Goods CMP: Rs914 Target Price: Rs1,109 Upside: 21%

Institutional Equities

Institutional Equities

Institutional Equities

La Opala RG. Institutional Equities. 4QFY17 Result Update UNDER REVIEW. Revenues Soar, But Margins Take A Hit. Sector: Tableware CMP: Rs536

Atul Auto. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Automobile CMP: Rs445 Target Price: Rs489 Upside: 10% 23 August 2017

KEC International. Institutional Equities. Management Meet Update BUY. On Course Towards Recovery In Operating Margin

Punjab National Bank

South Indian Bank. Institutional Equities. 1QFY19 Result Update. Performance Troughs, Pessimism Peaks BUY. 23 July 2018

9,251 7,812 8, NIM

9,807 8,007 9, NIM

Punjab National Bank

Swiss Glascoat Equipments

Cadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514

Hindustan Unilever. Institutional Equities. 2QFY19 Result Update

Hindustan Unilever. Institutional Equities. 3QFY18 Result Update BUY

Punjab National Bank

State Bank of India. Institutional Equities. 1QFY18 Result Update

Federal Bank. Institutional Equities. Management Meet Update

State Bank of India. Institutional Equities. 3QFY19 Result Update BUY

Manappuram Finance. Institutional Equities. 2QFY19 Result Update BUY

Sun Pharmaceutical Industries

Transcription:

Event Update The Ramco Cements 21 December 2018 Reuters: TRCE.BO; Bloomberg: TRCL IN Capacity Expansion To Boost Its Presence In Andhra & Telangana The Ramco Cements (TRCL) has announced 3.15mt cement capacity greenfield expansion in Kurnool district of Andhra Pradesh (AP) in South India. This is in addition to the satellite grinding units that will be commissioned in FY20 (see details below). The integrated unit in Kurnool will have a clinker capacity of 1.8mt. This will help TRCL in addressing the clinkerconversion mismatch and also boost its presence in the strong markets of AP and Telangana. TRCL is addressing its key power requirement for the new capacity by adding 18MW captive power unit and ~20MW of waste heat recovery system. Further, the unit is backed by a railway siding that will help control logistics cost. TRCL is progressing smoothly in commissioning its new grinding unit at Jajpur in Odisha (0.9mt by 2HFY20), expansion of Kolaghat (West Bengal) grinding unit to 2mt (by 1QFY20) and adding 1mt capacity at its Vizag grinding unit (by 4QFY20). After this entire capital expenditure, TRCL s cement capacity will jump to 24mt (with 13.4mt clinker capacity). The capex that will be incurred on new capacity addition (3.15mt) in AP is ~Rs15bn. This, along with the pending capex announced earlier (grinding units) and expansion of clinker facility at Jayantipuram (AP),implies a total capex of ~Rs35bn till FY20E/FY21E. The capex will be largely funded by internal accruals. We have, however, assumed a debt component of Rs7bn to complete the capex. We have factored in only a marginal impact of the earlier capex in FY20E, but factored in the same in FY21E. We are factoring only a limited impact of the new capex at Kurnool in FY21E (largely to the extent of benefits of clinkerisation) as we factor in some delay in completion and additionally higher gestation period for the greenfield project to stabilise. Hence, our FY21 estimates have been marginally revised upwards. We have retained Buy rating on TRCL with an target price of Rs741 ( from Rs680 earlier). Gaining sizeable presence in AP/Telangana: TRCL is steadily gaining a greater presence (proportion in total volume by capacity) in the strong AP/Telangana markets where relatively it had a weak presence (22% in FY16). With the grinding unit Vizag and new capacity addition in Kurnool, TRCL will gain a sizeable presence (37% in FY21E) in AP and Telangana markets. Additionally, it will also address clinker requirement in the eastern region at a rationalised logistics cost as compared earlier. Steadily moving towards a balanced clinker conversion ratio: TRCL had announced the clinker expansion earlier at Jayantipuram (AP) by 4QFY20. The new capacity addition at Kurnool is also expected to get completed at the same time. With incremental 3.3mt (1.5mt at Jayantipuram and 1.8mt new greenfield capacity) clinker capacity, TRCL will address clinker shortage in a major way in the strong growth markets. Further, this will also help TRCL to increase its presence in the eastern region with the help of higher utilisation of its grinding units with better cost management (reducing the inward logistics cost of clinker). Capex funding largely through internal accruals: TRCL plans to fund ~Rs35bn capex largely through internal accruals. With annual cash generation of ~ Rs10bn (in FY19E) and a steady growth rate, the capex can be funded without debt. However, assuming the worst-case scenario, we have factored in a debt of Rs7bn for capex completion. This will only marginally impact the debt- equity ratio from 0.15x to 0.3x in FY20E/FY21E. Further, with the strong interest coverage ratio (~8x/10x) the additional debt (based on our assumption) is unlikely to impact the balance sheet health in a major way. Limited earnings accretion in FY21E, full impact post FY21E: Though the intended capex is expected to be completed by FY20 factoring in the delay and higher stabilisation for the greenfield project, we have taken only a marginal contribution from the new capacities in FY21E (we have already factored in the contribution from new grinding units in our FY20/FY21 estimates). Hence we have maintained our FY19/FY20 earnings estimates and only marginally revised upwards our FY21 EPS estimate to Rs37.5 (from Rs36.3 earlier) factoring in lower operational benefits and the impact of interest cost/depreciation. We have valued TRCL at a replacement cost of Rs9.4bn/mt assigned it to average operating cement capacity of 18.7mt (based on expanded clinker capacity in September 2020E)) and excess grinding capacity (5mt) at Rs2.5bn to arrive at a target price of Rs741 (revised from Rs688 earlier). We believe TRCL s performance largely correlates with its home markets like Tamil Nadu and Kerala which are reviving and help TRCL to outperform its peers. Further, it is adding structural strength by focusing on regional diversification (eastern region) and cost-tightening measures. The current performance (because of a combination of tepid realisation and escalated costs) is expected to recover as demand from core markets revives. We have retained Buy rating on TRCL. At our target price of Rs741, the stock trades at EV/EBITDA of 13.3x September 2020 estimated earnings. BUY Sector: Cement CMP: Rs633 Target Price: Rs741 Upside: 17% Milind Raginwar Research Analyst milind.raginwar@nirmalbang.com +91-22-6273 8172 Key Data Current Shares O/S (mn) 235.6 Mkt Cap (Rsbn/US$bn) 148.2/2.1 52 Wk H / L (Rs) 879/546 Daily Vol. (3M NSE Avg.) 272,191 Price Performance (%) 1 M 6 M 1 Yr The Ramco Cements 0.2 (8.7) (20.7) Nifty Index 1.5 0.1 3.0 Source: Bloomberg

FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19E FY20E FY21E Exhibit 1: Financial key data Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E Net sales 39,302 43,851 48,220 54,367 68,105 growth (%) 10.7 11.6 10.0 12.7 25.3 EBITDA margin (%) 29.4 24.5 22.5 23.9 23.0 Adjusted net profit 6,493 5,525 6,317 7,626 8,835 versus consensus - - 16.7 10.2 (2.4) EPS (Rs) 27.3 23.3 26.8 32.4 37.5 growth (%) 19.8 (14.5) 14.9 20.7 15.9 P/E (x) 23.2 27.1 23.6 19.6 16.9 P/B (x) 4.1 3.7 3.2 2.8 2.5 EV/EBITDA (x) 13.9 14.8 14.5 12.7 10.5 D/E (x) 0.3 0.2 0.1 0.3 0.2 RoE (%) 19.2 14.4 14.6 15.5 15.6 RoCE (%) 17.3 14.8 14.6 15.9 15.9 Dividend yield (%) 0.5 0.5 0.5 0.5 0.5 Source: Company, Nirmal Bang Research Exhibit 2: Prudent capacity addition aided TRCL s performance in the past (MnT) 30 Capacity Vs Production 25 20 15 10 5 0 Cement Capacity (MnT) Cement Produced (MnT) Source: Company, Nirmal Bang Research Exhibit 3: Presence in strong AP and Telangana markets improving steadily alongside markets in eastern region Capacity across regions before proposed expansion 2% 22% 6% East Capacity across regions post proposed expansion 1% 12% East Tamil Nadu 37% Tamil Nadu AP AP 70% Karnataka 50% Karnataka Source: Company, Nirmal Bang Research 2 The Ramco Cements

FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19E FY20E FY21E Exhibit 4: Timely capacity addition helped TRCL to improve its presence in home market and add new markets 3.50 New capacity addition 3.00 2.50 2.00 1.50 1.00 Target Markets 0.50 0.00 Source: Company, Nirmal Bang Research Exhibit 5: Our revised earnings estimates (Rsmn) Old New Change (%) FY19E FY20E FY21E FY19E FY20E FY21E FY19E FY20E FY21E Net sales 48,435 53,991 62,864 48,220 54,367 68,105 (0.4) 0.7 8.3 Operating profit 10,856 12,720 14,538 10,851 12,990 15,696 (0.0) 2.1 8.0 Net profit 6,320 7,622 8,552 6,317 7,626 8,835 (0.1) 0.1 3.3 EPS (Rs) 26.8 32.4 36.3 26.8 32.4 37.5 (0.1) 0.1 3.3 Target price (Rs) 680 741 Rating Buy Buy Source: Company, Nirmal Bang Research 3 The Ramco Cements

Apr-08 Aug-08 Jan-09 Jun-09 Nov-09 Mar-10 Aug-10 Jan-11 Jun-11 Oct-11 Mar-12 Aug-12 Jan-13 May-13 Oct-13 Mar-14 Aug-14 Dec-14 May-15 Oct-15 Mar-16 Aug-16 Dec-16 May-17 Oct-17 Mar-18 Jul-18 Dec-18 Apr-08 Aug-08 Jan-09 Jun-09 Nov-09 Mar-10 Aug-10 Jan-11 Jun-11 Oct-11 Mar-12 Aug-12 Jan-13 May-13 Oct-13 Mar-14 Aug-14 Dec-14 May-15 Oct-15 Mar-16 Aug-16 Dec-16 May-17 Oct-17 Mar-18 Jul-18 Dec-18 Exhibit 6: One-year forward EV/EBITDA (Rs) 1,000 800 600 400 200 0 Source: Company, Nirmal Bang Research Price 8 10 12 14 Exhibit 7: One-year forward EV/tn (Rs) 800 600 400 200 0 Price $80 $100 $120 $140 $160 Source: Company, Nirmal Bang Research 4 The Ramco Cements

Financials Exhibit 8: Income statement Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E Net sales 39,302 43,851 48,220 54,367 68,105 Growth (%) 10.7 11.6 10.0 12.7 25.3 Operating expenses (27,731) (33,101) (37,369) (41,378) (52,409) EBITDA 11,571 10,750 10,851 12,990 15,696 Growth (%) 10.2 (7.1) 0.9 19.7 20.8 Depreciation & amortisation (2,655) (2,922) (2,746) (2,614) (3,514) EBIT 9,537 8,407 8,722 11,022 12,857 Other income 621 579 616 646 676 Interest paid (1,035) (592) (524) (1,016) (1,129) Extraordinary/\exceptional items PBT 8,501 7,815 8,198 10,006 11,728 Tax (2,009) (2,290) (1,882) (2,379) (2,893) Effective tax rate (%) (23.6) (29.3) (23.0) (23.8) (24.7) Net profit 6,493 5,525 6,317 7,626 8,835 Minority interest 0 0 0 0 0 Reported net profit 6,493 5,525 6,317 7,626 8,835 Non-recurring items 0 0 0 0 0 Adjusted net profit 6,493 5,525 6,317 7,626 8,835 Growth (%) 19.8 (14.9) 14.3 20.7 15.9 Source: Company, Nirmal Bang Research Exhibit 10: Balance sheet Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E Cash & bank balances 1,181 1,194 910 754 881 Other current assets 14,392 13,387 16,362 19,170 24,024 Investments 1,483 1,539 1,393 1,394 1,394 Net fixed assets 52,395 54,155 57,584 70,652 75,272 Goodwill & intangible assets 638 575 815 1,055 1,295 Other non-current assets 0 0 0 0 0 Total assets 70,088 70,850 77,064 93,025 102,867 Current liabilities 14,731 12,783 15,313 16,283 18,025 Borrowings 11,496 10,117 7,767 15,467 15,067 Other non-current liabilities 7,281 7,597 8,097 8,597 9,097 Total liabilities 33,509 30,496 31,177 40,346 42,188 Share capital 238 236 236 236 236 Reserves & surplus 36,341 40,171 45,652 52,443 60,443 Shareholders' funds 36,579 40,354 45,888 52,679 60,679 Minority interest 0 0 0 0 0 Total equity & liabilities 70,088 70,850 77,064 93,025 102,867 Source: Company, Nirmal Bang Research Exhibit 9: Cash flow Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E Pre-tax profit 8,501 7,815 8,198 10,006 11,728 Depreciation 2,347 2,556 4,224 4,284 5,857 Chg. in working capital 102 (1,197) (2,599) (2,336) (3,625) Total tax paid (1,882) (1,975) 422 (1,382) (1,879) Other operating activities 0 0 0 0 0 Operating CF 9,068 7,199 10,245 10,572 12,080 Capital expenditure (2,625) (4,254) (7,893) (17,593) (10,718) Chg. in investments (42) (56) 145 (1) 0 Other investment activities 0 0 0 0 0 Investing CF (2,667) (4,309) (7,748) (17,594) (10,718) FCF 6,401 2,890 2,497 (7,021) 1,363 Equity raised/(repaid) 0 (56) 53 0 0 Debt raised/(repaid) (5,358) (1,380) (2,350) 7,700 (400) Dividend (incl. tax) (757) (598) (484) (835) (835) Other financing activities (13) (843) 0 0 0 Financing CF (6,128) (2,876) (2,781) 6,865 (1,235) Net chg. in cash & bank bal. 273 13 (284) (156) 127 Closing cash & bank bal. 1,181 1,194 910 754 881 Source: Company, Nirmal Bang Research Exhibit 11: Key ratios Y/E March FY17 FY18 FY19E FY20E FY21E Profitability and return ratios (%) EBITDAM 29.4 24.5 22.5 23.9 23.0 EBITM 24.3 19.2 18.1 20.3 18.9 NPM 16.5 12.6 13.1 14.0 13.0 RoE 19.2 14.4 14.6 15.5 15.6 RoCE 17.3 14.8 14.6 15.9 15.9 RoIC 13.8 11.0 11.7 12.5 12.3 Per share data (Rs) O/s shares 238.1 236.9 235.6 235.6 235.6 EPS 27.3 23.3 26.8 32.4 37.5 FDEPS 27.3 23.3 26.8 32.4 37.5 CEPS 38.4 35.7 38.5 43.5 52.4 BV 153.6 170.4 194.8 223.6 257.5 DPS 3.0 3.0 3.0 3.0 3.0 Valuation ratios (x) P/E 23.2 27.1 23.6 19.6 16.9 P/BV 4.1 3.7 3.2 2.8 2.5 EV/EBITDA 13.9 14.8 14.5 12.7 10.5 EV/Sales 4.1 3.6 3.3 3.0 2.4 Other key ratios D/E (x) 0.3 0.2 0.1 0.3 0.2 DSO (days) 52 37 41 42 43 DuPont analysis - RoE NPM (%) 16.5 12.6 13.1 14.0 13.0 Asset turnover (x) 0.6 0.6 0.7 0.6 0.7 Equity multiplier (x) 2.1 1.8 1.7 1.7 1.7 RoE (%) 19.2 14.4 14.6 15.5 15.6 Source: Company, Nirmal Bang Research 5 The Ramco Cements

Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Rating track Date Rating Market price (Rs) Target price (Rs) 26 March 2018 Buy 796 887 24 May 2018 Buy 798 894 6 June 2018 Buy 746 894 3 August 2018 Buy 679 813 31 October 2018 Buy 596 688 21 December 2018 Buy 633 741 Rating track graph 900 850 800 750 700 650 600 550 500 Not Covered Covered 6 The Ramco Cements

DISCLOSURES This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as NBEPL ) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments. NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets. NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company. Analyst Certification: Mr. Milind Raginwar, the Research Analyst is the author of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. 7 The Ramco Cements

Disclaimer Stock Ratings Absolute Returns BUY > 15% ACCUMULATE -5% to15% SELL < -5% This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions. The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and noninfringement. The recipients of this report should rely on their own investigations. This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report. Copyright of this document vests exclusively with NBEPL. Our reports are also available on our website www.nirmalbang.com Access all our reports on Bloomberg, Thomson Reuters and Factset. Team Details: Name Email Id Direct Line Rahul Arora CEO rahul.arora@nirmalbang.com - Girish Pai Head of Research girish.pai@nirmalbang.com +91 22 6273 8017 / 18 Dealing Ravi Jagtiani Dealing Desk ravi.jagtiani@nirmalbang.com +91 22 6273 8230, +91 22 6636 8833 Pradeep Kasat Dealing Desk pradeep.kasat@nirmalbang.com +91 22 6273 8100/8101, +91 22 6636 8831 Michael Pillai Dealing Desk michael.pillai@nirmalbang.com +91 22 6273 8102/8103, +91 22 6636 8830 Nirmal Bang Equities Pvt. Ltd. Correspondence Address B-2, 301/302, Marathon Innova, Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai-400013. Board No. : 91 22 6273 8000/1; Fax. : 022 6273 8010 8 The Ramco Cements